Login Register Cart 0
Generic placeholder image

Current Organocatalysis

Editor-in-Chief

ISSN (Print): 2213-3372
ISSN (Online): 2213-3380

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Opinion Article

More Widespread use of Ivermectin for the Treatment of COVID-19 Infection could have Saved Many

Author(s): Alberto Boretti* and Bimal K. Banik

Volume 11, Issue 2, 2024

Published on: 10 October, 2023

Page: [89 - 94] Pages: 6

DOI: 10.2174/2213337210666230809141610

Price: $65

conference banner
Abstract

Here we review the available literature for the specific use of Ivermectin against COVID-19 infection. Currently, 204 works have been published presenting the results of ivermectin use for COVID- 19. 156 are peer-reviewed, and 96 are comparing treatment and control groups. Ivermectin was adopted for early treatment in all or part of 22 countries (39 including non-government medical organizations). The 96 studies of Ivermectin for COVID-19 were published by 1,030 scientists, reporting the cases of 135,554 patients in 27 countries. These studies show a statistically significant improvement in mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance. Specifically, improvements recorded were 85%, 62%, and 43% for prophylaxis, early, and late treatment, with confidence intervals (CI) (77-90%), (51-70%), (28-54%) respectively. A 56%improvement was recorded in the 45 randomized controlled trials (RCTs) with CI (41-68%). A 51% lower mortality was evidenced from 49 studies with CI (37-61%). In February 2021, when the war on Ivermectin started in the West, it was clear that this drug had positive effects, working in vivo/in vitro , and delivering mostly positive results in clinical trials. More widespread use of Ivermectin could have saved many people, and suppression of this drug in many countries that had very high cumulative fatalities per million people has been a very unfortunate occurrence for science.

« Previous
Graphical Abstract

[1]
Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS CoV-2 in vitro. Antiviral Res., 2020, 178, 104787.
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[2]
Momekov, G.; Momekova, D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens. Biotechnol. Biotechnol. Equip., 2020, 34(1), 469-474.
[http://dx.doi.org/10.1080/13102818.2020.1775118]
[3]
Chaccour, C.; Hammann, F.; Ramón-García, S.; Rabinovich, N.R. Ivermectin and COVID-19: Keeping rigor in times of urgency. Am. J. Trop. Med. Hyg., 2020, 102(6), 1156-1157.
[http://dx.doi.org/10.4269/ajtmh.20-0271] [PMID: 32314704]
[4]
Coronavirus Disease 2019 (COVID-19) Treatment & Management. Available from: www.medscape.com/answers/2500114-197513/what-is-the-role-of-the-antiparasitic-drug-ivermectin-inthe-treatment-of-coronavirus-disease-2019-covid-19
[5]
Ivermectin for COVID-19 Real-time meta analysis of 99 studies: Available from: c19ivm.org/
[6]
Lv, C.; Liu, W.; Wang, B.; Dang, R.; Qiu, L.; Ren, J.; Yan, C.; Yang, Z.; Wang, X. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and in vivo. Antiviral Res., 2018, 159, 55-62.
[http://dx.doi.org/10.1016/j.antiviral.2018.09.010] [PMID: 30266338]
[7]
Buonfrate, D.; Salas-Coronas, J.; Muñoz, J.; Maruri, B.T.; Rodari, P.; Castelli, F.; Zammarchi, L.; Bianchi, L.; Gobbi, F.; Cabezas-Fernández, T.; Requena-Mendez, A.; Godbole, G.; Silva, R.; Romero, M.; Chiodini, P.L.; Bisoffi, Z. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect. Dis., 2019, 19(11), 1181-1190.
[http://dx.doi.org/10.1016/S1473-3099(19)30289-0] [PMID: 31558376]
[8]
Laure, M.; Hamza, H.; Koch-Heier, J.; Quernheim, M.; Müller, C.; Schreiber, A.; Müller, G.; Pleschka, S.; Ludwig, S.; Planz, O. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Antiviral Res., 2020, 178, 104806.
[http://dx.doi.org/10.1016/j.antiviral.2020.104806] [PMID: 32304723]
[9]
Yang, S.N.Y.; Atkinson, S.C.; Wang, C.; Lee, A.; Bogoyevitch, M.A.; Borg, N.A.; Jans, D.A. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res., 2020, 177, 104760.
[http://dx.doi.org/10.1016/j.antiviral.2020.104760] [PMID: 32135219]
[10]
Heidary, F.; Gharebaghi, R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. J. Antibiot., 2020, 73(9), 593-602.
[http://dx.doi.org/10.1038/s41429-020-0336-z] [PMID: 32533071]
[11]
Patrì, A.; Fabbrocini, G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J. Am. Acad. Dermatol., 2020, 82(6), e221.
[http://dx.doi.org/10.1016/j.jaad.2020.04.017] [PMID: 32283237]
[12]
Carlosama-Rosero, Y. Ivermectina en COVID-19. Argumentum ad ignorantiam? Rev. Clin. Esp., 2020, 220(7), 457-458.
[http://dx.doi.org/10.1016/j.rce.2020.06.003]
[13]
Jans, D.A.; Wagstaff, K.M. Ivermectin as a broad-spectrum host-directed antiviral: The real deal? Cells, 2020, 9(9), 2100.
[http://dx.doi.org/10.3390/cells9092100] [PMID: 32942671]
[14]
Lehrer, S.; Rheinstein, P.H. Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In vivo, 2020, 34(5), 3023-3026.
[15]
Francés-Monerris, A.; Garcia-Iriepa, C.; Iriepa, I.; Hognon, C.; Miclot, T.; Barone, G.; Monari, A.; Marazzi, M. Has ivermectin virus-directed effects against SARS-CoV-2? rationalizing the action of a potential multitarget antiviral agent; Chemrix, 2020.
[16]
Li, N.; Zhao, L.; Zhan, X. Quantitative proteomics reveals a broad spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J. Cell. Physiol., 2021, 236(4), 2959-2975.
[http://dx.doi.org/10.1002/jcp.30055] [PMID: 32959892]
[17]
de Melo, G.D.; Lazarini, F.; Larrous, F.; Feige, L.; Kergoat, L.; Marchio, A.; Pineau, P.; Lecuit, M.; Lledo, P.M.; Changeux, J.P.; Bourhy, H. Anti-COVID-19 efficacy of ivermectin in the golden hamster. BioRxiv, 2020, 2020-11.
[http://dx.doi.org/10.1101/2020.11.21.392639]
[18]
Arévalo, A.P.; Pagotto, R.; Pórfido, J.L.; Daghero, H.; Segovia, M.; Yamasaki, K.; Varela, B.; Hill, M.; Verdes, J.M.; Duhalde Vega, M.; Bollati-Fogolín, M.; Crispo, M. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Sci. Rep., 2021, 11(1), 7132.
[http://dx.doi.org/10.1038/s41598-021-86679-0] [PMID: 33785846]
[19]
Gheibi, N.; Shakhsi Niaee, M.; Namdar, P.; Allami, A.; Zolghadr, L.; Javadi, A.; Karampour, A.; Varnaseri, M.; Bijani, B.; Cheraghi, F.; Naderi, Y.; Amini, F.; Karamyan, M. YadYad, M.J.; Jamshidian, R. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Asian Pac. J. Trop. Med., 2021, 14(6), 266.
[http://dx.doi.org/10.4103/1995-7645.318304]
[20]
Budhiraja, S.; Soni, A.; Jha, V.; Indrayan, A.; Dewan, A.; Singh, O.; Singh, Y.P.; Chugh, I.; Arora, V.; Pande, R.; Ansari, A. Clinical Profile of First 1000 COVID-19 cases admitted at tertiary care hospitals and the correlates of their mortality: An Indian experience. MedRxiv, 2020, 2020-11.
[http://dx.doi.org/10.1101/2020.11.16.20232223]
[21]
Spoorthi, V.; Sasank, S. Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV2. Int. Arch. Integrated Med., 2020, 7(10), 177-182.
[22]
Elgazzar, A.; Eltaweel, A.; Youssef, S.A.; Hany, B.; Hafez, M.; Moussa, H. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square, 2020.
[http://dx.doi.org/10.21203/rs.3.rs-100956/v2]
[23]
Cadegiani, F.A.; Goren, A.; Wambier, C.G.; McCoy, J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes New Infect., 2021, 43, 100915.
[http://dx.doi.org/10.1016/j.nmni.2021.100915] [PMID: 34249367]
[24]
Morgenstern, J.; Redondo, J.N.; De León, A.; Canela, J.M.; Torres, N.; Tavares, J.; Minaya, M.; López, Ó.; María Plácido, A.; Castillo, A.; Peña Cruz, R. The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10 2020MedRxiv, , 2020.
[http://dx.doi.org/10.1101/2020.10.29.20222505]
[25]
Behera, P.; Patro, B.; Singh, A.; Chandanshive, P.; Kumar, R.; Pradhan, S. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study. MedRxiv, 2020, 10.
[http://dx.doi.org/10.1101/2020.10.29.20222661]
[26]
Hashim, H.A.; Maulood, M.F.; Rasheed, A.M.; Fatak, D.F.; Kabah, K.K.; Abdulamir, A.S. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. MedRxiv, 2020, 2020-10.
[http://dx.doi.org/10.1101/2020.10.26.20219345]
[27]
Rajter, J.C.; Sherman, M.S.; Fatteh, N.; Vogel, F.; Sacks, J.; Rajter, J.J. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study. Chest, 2021, 159(1), 85-92.
[http://dx.doi.org/10.1016/j.chest.2020.10.009] [PMID: 33065103]
[28]
Reaz, M. Clinical trial of ivermectin plus doxycycline for the treatment of confirmed Covid-19 infection. Patent NCT04523831, 2020.
[29]
Chang, G.A. Inclusión de la ivermectinaen La primeralínea de acciónterapéutica para COVID-19. 2020.
[http://dx.doi.org/10.13140/RG.2.2.34689.48482/7]
[30]
Khan, M.S.I.; Khan, M.S.I.; Debnath, C.R.; Nath, P.N.; Al Mahtab, M.; Nabeka, H.; Matsuda, S.; Akbar, S.M.F. Ivermectin treatment may improve the prognosis of patients with COVID-19. Arch. Bronconeumol., 2020, 56(12), 828.
[31]
Carvallo, H.E.; Hirsch, R.R.; Farinella, M.E. Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. MedRxiv, 2020.
[http://dx.doi.org/10.1101/2020.09.10.20191619]
[32]
Podder, C.S.; Chowdhury, N.; Sina, M.I.; Haque, W.M.M.U. Outcome of ivermectin treated mild to moderate COVID-19 cases: A single-centre, open-label, randomised controlled study. IMC J. Med. Sci., 2021, 14(2), 11-18.
[http://dx.doi.org/10.3329/imcjms.v14i2.52826]
[33]
Positive results of the iver.car protocol in the prophylaxis of health agents. Available from: www.pharmabaires.com/1739-resultados-positivos-del-protocolo-iver-car-en-la-profilaxis-de-los-agentes-de-salud.html
[34]
Shouman, W. Use of ivermectin as a prophylactic option in asymptomatic family close contact for patient with COVID-19. Patent NCT04422561, 2020.
[35]
Espitia-Hernandez, G.; Munguia, L.; Diaz-Chiguer, D.; Lopez-Elizalde, R.; Jimenez-Ponce, F. Effects of Ivermectin-azithromycin cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomed. Res., 2020, 31(5), 129-133.
[36]
Bhattacharya, R.; Ghosh, R.; Kulshrestha, M.; Chowdhury, S.; Mukherjee, R.; Ray, I. Observational study on clinical features, treatment and outcome of COVID 19 in a tertiary care Centre in India-a retrospective case series. MedRxiv, 2020, 2020-08.
[http://dx.doi.org/10.1101/2020.08.12.20170282]
[37]
Alam, M.T.; Murshed, R.; Bhiuyan, E.; Saber, S.; Alam, R.F.; Robin, R.C. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. J. Bangladesh Coll. Phys. Surg., 2020, 38, 10-15.
[http://dx.doi.org/10.3329/jbcps.v38i0.47512]
[38]
Rahman, M.A.; Iqbal, S.A.; Islam, M.A.; Niaz, M.K.; Hussain, T.; Siddiquee, T.H. Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. J. Bangladesh Coll. Phys. Surg., 2020, 38, 5-9.
[http://dx.doi.org/10.3329/jbcps.v38i0.47514]
[39]
Gorial, F.I.; Mashhadani, S.; Sayaly, H.M.; Dakhil, B.D.; AlMashhadani, M.M.; Aljabory, A.M.; Abbas, H.M.; Ghanim, M.; Rasheed, J.I. Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial). MedRxiv, 2020, 2020-07.
[http://dx.doi.org/10.1101/2020.07.07.20145979]
[40]
Krolewiecki, A.; Lifschitz, A.; Moragas, M.; Travacio, M.; Valentini, R.; Alonso, D.F.; Solari, R.; Tinelli, M.A.; Cimino, R.O.; Álvarez, L.; Fleitas, P.E. Antiviral effect of high-dose ivermectin in adults with COVID-19: A pilot randomised, controlled, open label, multicentre trial. SSRN, 2020.
[http://dx.doi.org/10.2139/ssrn.3714649]
[41]
Camprubí, D.; Almuedo-Riera, A.; Martí-Soler, H.; Soriano, A.; Hurtado, J.C.; Subirà, C.; Grau-Pujol, B.; Krolewiecki, A.; Muñoz, J. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One, 2020, 15(11), e0242184.
[http://dx.doi.org/10.1371/journal.pone.0242184] [PMID: 33175880]
[42]
Zeeshan, K.C.A.; Ahmad, K.K.; Asif, M.; Tanveer, K.; Khaqan, A.; Basri, R. Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. Int. J. Sci., 2020, 9(9), 31-35.
[http://dx.doi.org/10.18483/ijSci.2378]
[43]
Chowdhury, A.T.M.M.; Shahbaz, M.; Karim, M.R.; Islam, J.; Guo, D.; He, S. A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients. Research square, 2020.
[http://dx.doi.org/10.21203/rs.3.rs-38896/v1]
[44]
War on ivermectin: The medicine that saved millions and could have ended the pandemic hardcover – June 6 2023. Available from: www.amazon.com/War-Ivermectin-Medicine-Millions-Pandemic/dp/151077386X
[45]
The Censorship Industrial Complex. Available from: judiciary.house.gov/sites/evo-subsites/republicans-judiciary.house.gov/files/evo-media-document/shellenberger-testimony.pdf
[46]
Report on the Censorship-Industrial Complex: The Top 50 Organizations to Know. 2020. Available from: https://www.racket.news/p/report-on-the-censorship-industrial-74b
[47]
Estimated cumulative excess deaths per 100,000 people during COVID-19 Nov 8;2023 Available from: ourworldindata.org/explorers/coronavirus-data-explorer

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy